TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status
TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status
Background: breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20,000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome.
Methods: we selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome.
Results: of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records.
Conclusions: the whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.
Rahman, Fatima
a50a073c-50b5-4a43-bd57-0e178a2326ab
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Hales, Alan
66a20906-7b0e-4d23-b65a-08932f23900b
Rew, David
36dcc3ad-2379-4b61-a468-5c623d796887
Rahman, Fatima
a50a073c-50b5-4a43-bd57-0e178a2326ab
Copson, Ellen
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Hales, Alan
66a20906-7b0e-4d23-b65a-08932f23900b
Rew, David
36dcc3ad-2379-4b61-a468-5c623d796887
Rahman, Fatima, Copson, Ellen, Hales, Alan and Rew, David
(2021)
TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status.
British Journal of Surgery, 108 (Supplement_7).
(doi:10.1093/bjs/znab362.069).
Record type:
Meeting abstract
Abstract
Background: breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20,000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome.
Methods: we selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome.
Results: of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records.
Conclusions: the whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.
This record has no associated files available for download.
More information
e-pub ahead of print date: 28 October 2021
Identifiers
Local EPrints ID: 455957
URI: http://eprints.soton.ac.uk/id/eprint/455957
ISSN: 0007-1323
PURE UUID: c01516d8-7695-4b1c-921b-681d0c37d6be
Catalogue record
Date deposited: 11 Apr 2022 16:37
Last modified: 17 Mar 2024 03:56
Export record
Altmetrics
Contributors
Author:
Fatima Rahman
Author:
Alan Hales
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
